Years in the unmaking, CTI’s Pixuvri fails a pivotal PhIII combo study for lymphoma — can it remain on the market?

Seattle-based CTI BioPharma’s $CTIC years-long saga developing Pixuvri (pixantrone) has run into another stone wall. The company reported today that the drug, given conditional approval in Europe 6 years ago, failed a Phase III combination study in B-cell non-Hodgkin lymphoma.